ChartRow logo
Sign in
Share this page
MDGL
$499.40-0.06%
as of close, Oct 2, 2026
☾ AH $499.40 -0.06%
Madrigal Pharmaceuticals Inc.Stock · Health CareNasdaq Composite 0.02%Russell 1000 0.01%US Stock Market 0.01%Russell 3000 0.01%
PeersMRNALLYUNHJNJMRKTMO

MDGL SEC filings (2026)

CIK 1157601 · Pharmaceutical Preparations (SIC 2834) · incorporated in DE · fiscal year ends in December

1,217 filings on EDGAR since 2002 · 24 annual, 61 quarterly, 190 current · financial statements · earnings

Latest 10-K
Feb 19, 2026
fiscal year to Dec 31, 2025
Latest 10-Q
Jul 30, 2026
quarter to Jun 30, 2026
Latest 8-K
Aug 12, 2026
Directors or officers; compensation; Regulation FD disclosure
Last earnings release
Jul 30, 2026
−$1.99 vs −$2.55 · ▼ 9.8%
Filings on file
1,217
since 2002, 652 insider forms

What happened, last 12 months#

Every earnings release with its print, every report with its quarter, the other 8-Ks by what they covered, the proxy statements, and each day an insider bought or sold — newest first, each line opening the filing on EDGAR. The index by form and year follows.

September 2026

August 2026

July 2026

June 2026

May 2026

April 2026

March 2026

February 2026

January 2026

December 2025

November 2025

Insider transactions#

What officers, directors and 10% holders reported on Forms 4 and 5 over the last 13 months, from the documents themselves: one insider’s trades of one kind on one day are one row, with the shares, the price range and the total as filed. Open-market buys and sells first; awards, exercises, tax withholding, gifts and employee-plan purchases are grouped below them.

Over the last 13 months insiders sold $40.2M in 20 sales and bought nothing on the open market; 36 other transactions (awards, exercises, tax withholding, gifts and plan purchases).

DateInsider
Sep 11, 2026Form 4Sibold William JohnPresident and CEO · DirectorSold · $2.8M · 5,221 sh · 10b5-1
Sep 9, 2026Form 4Sibold William JohnPresident and CEO · DirectorSold · $3.4M · 6,362 sh · 10b5-1
Aug 17, 2026Form 4Kelley Shannon TGeneral CounselSold · $342K · 664 sh
Jul 20, 2026Form 4Sibold William JohnPresident and CEO · DirectorSold · $1.4M · 2,500 sh
Jun 1, 2026Form 4Soergel DavidChief Medical OfficerSold · $517K · 1,042 sh · 10b5-1
May 22, 2026Form 4Levy Richard SDirectorSold · $2.9M · 5,682 sh · 10b5-1
May 18, 2026Form 4Soergel DavidChief Medical OfficerSold · $435K · 844 sh
Mar 6, 2026Form 4Dier MardiEVP and CFOSold · $854K · 1,982 sh · 10b5-1
Mar 6, 2026Form 4Sibold William JohnPresident and CEO · DirectorSold · $718K · 1,663 sh
Mar 6, 2026Form 4Taub RebeccaDirectorSold · $212K · 491 sh
Mar 6, 2026Form 4Huntsman CaroleChief Commercial OfficerSold · $181K · 419 sh
Mar 6, 2026Form 4Kelley Shannon TGeneral CounselSold · $155K · 360 sh
Mar 2, 2026Form 4Dier MardiEVP and CFOSold · $505K · 1,183 sh
Jan 26, 2026Form 4Sibold William JohnPresident and CEO · DirectorSold · $777K · 1,577 sh
Jan 26, 2026Form 4Huntsman CaroleChief Commercial OfficerSold · $449K · 910 sh · 10b5-1
Jan 26, 2026Form 4Taub RebeccaDirectorSold · $319K · 647 sh
Jan 20, 2026Form 4Taub RebeccaDirectorSold · $1.1M · 2,238 sh
Jan 20, 2026Form 4Kelley Shannon TGeneral CounselSold · $344K · 692 sh · 10b5-1
Jan 9, 2026Form 4 ×2FRIEDMAN PAUL ADirectorSold · $13.0M · 24,800 sh · 10b5-1
Jan 9, 2026Form 4 ×2Taub RebeccaDirectorSold · $9.7M · 18,650 sh · 10b5-1
Awards, exercises, withholding and plan purchases · 36 transactions
DateInsider
Aug 15, 2026Form 4REED JOHN CDirectorAward · Stock Option (Right to Buy) · $0 · 1,078 sh
Aug 15, 2026Form 4REED JOHN CDirectorAward · $0 · 647 sh
Jul 17, 2026Form 4Sibold William JohnPresident and CEO · DirectorExercise or conversion · — · 50,000 sh
Jul 17, 2026Form 4Sibold William JohnPresident and CEO · DirectorExercise or conversion · Performance Restricted Sto… · $0 · 50,000 sh
Jun 17, 2026Form 4BAKER BROS. ADVISORS LP, 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN6 filersAward · Non-Qualified Stock Option… · $0 · 3,064 sh
Jun 17, 2026Form 4BAKER BROS. ADVISORS LP, 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN6 filersAward · $0 · 1,816 sh
Jun 17, 2026Form 4Daly James MDirectorAward · Stock Option (Right to Buy) · $0 · 766 sh
Jun 17, 2026Form 4FOUSE JACQUALYN ADirectorAward · Stock Option (Right to Buy) · $0 · 766 sh
Jun 17, 2026Form 4Levy Richard SDirectorAward · Stock Option (Right to Buy) · $0 · 766 sh
Jun 17, 2026Form 4Taub RebeccaDirectorAward · Stock Option (Right to Buy) · $0 · 766 sh
Jun 17, 2026Form 4Brennan Daniel J.DirectorAward · Stock Option (Right to Buy) · $0 · 681 sh
Jun 17, 2026Form 4Daly James MDirectorAward · $0 · 454 sh
Jun 17, 2026Form 4FOUSE JACQUALYN ADirectorAward · $0 · 454 sh
Jun 17, 2026Form 4Levy Richard SDirectorAward · $0 · 454 sh
Jun 17, 2026Form 4Taub RebeccaDirectorAward · $0 · 454 sh
Jun 17, 2026Form 4Brennan Daniel J.DirectorAward · $0 · 404 sh
Mar 4, 2026Form 4Sibold William JohnPresident and CEO · DirectorAward · Stock Option (Right to Buy) · $0 · 18,743 sh
Mar 4, 2026Form 4Sibold William JohnPresident and CEO · DirectorAward · $0 · 14,995 sh
Mar 4, 2026Form 4Dier MardiEVP and CFOAward · Stock Option (Right to Buy) · $0 · 6,519 sh · 10b5-1
Mar 4, 2026Form 4Soergel DavidChief Medical OfficerAward · Stock Option (Right to Buy) · $0 · 5,467 sh
Mar 4, 2026Form 4Dier MardiEVP and CFOAward · $0 · 5,215 sh · 10b5-1
Mar 4, 2026Form 4Kelley Shannon TGeneral CounselAward · Stock Option (Right to Buy) · $0 · 5,022 sh
Mar 4, 2026Form 4Huntsman CaroleChief Commercial OfficerAward · Stock Option (Right to Buy) · $0 · 4,986 sh
Mar 4, 2026Form 4Soergel DavidChief Medical OfficerAward · $0 · 4,374 sh
Mar 4, 2026Form 4Kelley Shannon TGeneral CounselAward · $0 · 4,017 sh
Mar 4, 2026Form 4Huntsman CaroleChief Commercial OfficerAward · $0 · 3,989 sh
Feb 23, 2026Form 4Levy Richard SDirectorExercise or conversion · $18K · 2,500 sh
Feb 23, 2026Form 4Levy Richard SDirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 2,500 sh
Jan 26, 2026Form 4Levy Richard SDirectorExercise or conversion · $66K · 4,000 sh
Jan 26, 2026Form 4Levy Richard SDirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 4,000 sh
Jan 15, 2026Form 4Thakkar RitaChief Accounting OfficerAward · $0 · 2,398 sh
Jan 15, 2026Form 4Thakkar RitaChief Accounting OfficerAward · Stock Option (Right to Buy) · $0 · 1,826 sh
Jan 9, 2026Form 4 ×2FRIEDMAN PAUL ADirectorExercise or conversion · $392K · 24,800 sh · 10b5-1
Jan 9, 2026Form 4 ×2Taub RebeccaDirectorExercise or conversion · $295K · 18,650 sh · 10b5-1
Jan 9, 2026Form 4 ×2FRIEDMAN PAUL ADirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 24,800 sh · 10b5-1
Jan 9, 2026Form 4 ×2Taub RebeccaDirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 18,650 sh · 10b5-1

Reports and proxy statements#

Annual reports (10-K, 20-F, 40-F), quarterly reports (10-Q), current reports (8-K, 6-K) and proxy statements, newest first. An 8-K is described by its items. A form opens the document on EDGAR, or the filing’s index where it furnishes exhibits (an earnings release is the 8-K’s Exhibit 99.1).

2026 · 13 filings
FiledWhat it is
Aug 12, 20268-KDirectors or officers; compensation; Regulation FD disclosure
Jul 30, 202610-QQuarterly report, Q2 2026 — revenue $364.3M (+71% y/y), net income −$57.9M, EPS −$1.99
Jul 30, 20268-KEarnings release — EPS −$1.99 vs −$2.55 est. (+22.0%); revenue $364.3M (+71% y/y) 9.8%
Jun 17, 20268-KDirectors or officers; compensation; Shareholder vote results
May 6, 202610-QQuarterly report, Q1 2026 — revenue $311.3M (+127% y/y), net income −$94.4M, EPS −$3.25
May 6, 20268-KEarnings release — EPS −$3.25 vs −$3.61 est. (+10.0%); revenue $311.3M (+127% y/y) 7.4%
Apr 28, 20268-KDirectors or officers; compensation
Apr 28, 2026ARSAnnual report to shareholders
Apr 28, 2026DEFA14AAdditional proxy materials
Apr 28, 2026DEF 14AProxy statement
Feb 19, 202610-KAnnual report, FY2025 — revenue $958.4M (+432% y/y), net income −$288.3M, EPS −$10.15
Feb 19, 20268-KEarnings release — EPS −$2.57 vs $0.04 est. (−6525.0%); revenue $321.1M (+211% y/y) 11.1%
Jan 30, 20268-KMaterial definitive agreement
2025 · 18 filings
FiledWhat it is
Dec 11, 20258-KDirectors or officers; compensation
Nov 4, 202510-QQuarterly report, Q3 2025 — revenue $287.3M (+362% y/y), net income −$114.2M, EPS −$4.01
Nov 4, 20258-KEarnings release — EPS −$5.08 vs −$1.98 est. (−156.6%); revenue $287.3M (+362% y/y) 7.8%
Aug 5, 202510-QQuarterly report, Q2 2025 — revenue $212.8M (+1354% y/y), net income −$42.3M, EPS −$1.50
Aug 5, 20258-KResults of operations
Jul 30, 20258-KRegulation FD disclosure
Jul 22, 20258-KMaterial definitive agreement; Termination of a material agreement; New financial obligation; Regulation FD disclosure
Jun 20, 20258-KShareholder vote results
May 1, 202510-QQuarterly report, Q1 2025 — revenue $137.3M, net income −$73.2M, EPS −$2.61
May 1, 20258-KResults of operations
Apr 29, 2025ARSAnnual report to shareholders
Apr 29, 2025DEFA14AAdditional proxy materials
Apr 29, 2025DEF 14AProxy statement
Apr 17, 20258-KDirectors or officers; compensation
Mar 11, 20258-KDirectors or officers; compensation; Regulation FD disclosure
Feb 26, 202510-KAnnual report, FY2024 — revenue $180.1M, net income −$465.9M, EPS −$17.31
Feb 26, 20258-KResults of operations
Jan 13, 20258-KResults of operations
2024 · 18 filings
FiledWhat it is
Oct 31, 202410-QQuarterly report, Q3 2024 — revenue $62.2M, net income −$107.0M, EPS −$4.92
Oct 31, 20248-KResults of operations
Aug 7, 202410-QQuarterly report, Q2 2024 — revenue $14.6M, net income −$152.0M, EPS −$7.10
Aug 7, 20248-KResults of operations
Jun 27, 20248-KDirectors or officers; compensation; Shareholder vote results
May 7, 20248-KMaterial definitive agreement; Termination of a material agreement; Other events
May 7, 202410-QQuarterly report, Q1 2024 — revenue $0, net income −$147.5M, EPS −$7.38
May 7, 20248-KResults of operations
Apr 29, 2024ARSAnnual report to shareholders
Apr 29, 2024DEFA14AAdditional proxy materials
Apr 29, 2024DEF 14AProxy statement
Apr 2, 20248-KOther events
Mar 20, 20248-KMaterial definitive agreement
Mar 15, 20248-KRegulation FD disclosure; Other events
Feb 28, 20248-KDirectors or officers; compensation
Feb 28, 20248-KResults of operations
Feb 28, 202410-KAnnual report, FY2023 — revenue $0, net income −$373.6M, EPS −$17.33
Jan 8, 20248-KOther events
2023 · 24 filings — 16 × 8-K, 3 × 10-Q, 1 × 10-K and 4 other forms
FiledWhat it is
Nov 6, 202310-QQuarterly report, Q3 2023 — revenue $0, net income −$98.7M, EPS −$5.34
Aug 8, 202310-QQuarterly report, Q2 2023 — revenue $0, net income −$85.8M, EPS −$4.69
May 9, 202310-QQuarterly report, Q1 2023 — revenue $0, net income −$76.9M, EPS −$4.23
May 1, 2023DEFA14AAdditional proxy materials
May 1, 2023DEF 14AProxy statement
Apr 21, 2023PRE 14APreliminary proxy statement
Mar 3, 202310-K/AAnnual report, amended
Feb 23, 202310-KAnnual report

16 current reports (8-K) not listed; the year is on EDGAR.

2022 · 14 filings — 8 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
FiledWhat it is
Nov 3, 202210-QQuarterly report, Q3 2022 — revenue $0, net income −$81.2M, EPS −$4.75
Aug 4, 202210-QQuarterly report, Q2 2022 — revenue $0, net income −$70.7M, EPS −$4.14
May 9, 202210-QQuarterly report, Q1 2022 — revenue $0, net income −$57.5M, EPS −$3.36
May 2, 2022DEFA14AAdditional proxy materials
May 2, 2022DEF 14AProxy statement
Feb 24, 202210-KAnnual report, FY2021 — revenue $0, net income −$241.8M, EPS −$14.63

8 current reports (8-K) not listed; the year is on EDGAR.

2021 · 13 filings — 7 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
FiledWhat it is
Nov 4, 202110-QQuarterly report, Q3 2021 — revenue $0, net income −$63.1M, EPS −$3.79
Aug 5, 202110-QQuarterly report, Q2 2021 — revenue $0, net income −$61.7M, EPS −$3.72
May 6, 202110-QQuarterly report, Q1 2021 — revenue $0, net income −$52.5M, EPS −$3.32
Apr 30, 2021DEFA14AAdditional proxy materials
Apr 30, 2021DEF 14AProxy statement
Feb 25, 202110-KAnnual report, FY2020 — revenue $0, net income −$202.2M, EPS −$13.09

7 current reports (8-K) not listed; the year is on EDGAR.

2020 · 11 filings — 6 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
FiledWhat it is
Nov 5, 202010-QQuarterly report, Q3 2020 — revenue $0, net income −$58.0M
Aug 6, 202010-QQuarterly report, Q2 2020 — revenue $0, net income −$49.0M
May 7, 202010-QQuarterly report, Q1 2020 — revenue $0, net income −$36.1M
Apr 29, 2020DEF 14AProxy statement
Feb 26, 202010-KAnnual report, FY2019 — revenue $0, net income −$83.9M

6 current reports (8-K) not listed; the year is on EDGAR.

2019 · 15 filings — 8 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
FiledWhat it is
Nov 6, 201910-QQuarterly report, Q3 2019 — revenue $0, net income −$21.4M
Aug 7, 201910-QQuarterly report, Q2 2019 — revenue $0, net income −$19.7M
May 15, 2019DEFA14AAdditional proxy materials
May 15, 2019DEF 14AProxy statement
May 8, 201910-QQuarterly report, Q1 2019 — revenue $0, net income −$15.1M
Apr 30, 201910-K/AAnnual report, amended
Feb 27, 201910-KAnnual report, FY2018 — revenue $0, net income −$32.8M

8 current reports (8-K) not listed; the year is on EDGAR.

2018 · 13 filings — 7 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
FiledWhat it is
Nov 6, 201810-QQuarterly report, Q3 2018 — revenue $0, net income −$8.5M
Aug 7, 201810-QQuarterly report, Q2 2018 — revenue $0, net income −$6.5M
May 8, 201810-QQuarterly report, Q1 2018 — revenue $0, net income −$6.4M
Apr 27, 2018DEFA14AAdditional proxy materials
Apr 27, 2018DEF 14AProxy statement
Mar 13, 201810-KAnnual report, FY2017 — revenue $0, net income −$31.2M

7 current reports (8-K) not listed; the year is on EDGAR.

2017 · 15 filings — 9 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
FiledWhat it is
Nov 9, 201710-QQuarterly report, Q3 2017 — net income −$8.4M
Aug 10, 201710-QQuarterly report, Q2 2017 — net income −$8.3M
May 11, 201710-QQuarterly report, Q1 2017 — net income −$6.0M
Apr 28, 2017DEF 14AProxy statement
Mar 31, 201710-KAnnual report, FY2016 — net income −$26.4M
Mar 31, 201710-Q/AQuarterly report, amended

9 current reports (8-K) not listed; the year is on EDGAR.

2016 · 30 filings — 13 × 8-K, 8 × DEFA14A, 3 × 10-Q and 6 other forms

Counted, not listed; the year is on EDGAR.

2015 · 16 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms

Counted, not listed; the year is on EDGAR.

2014 · 18 filings — 12 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms

Counted, not listed; the year is on EDGAR.

2013 · 22 filings — 15 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms

Counted, not listed; the year is on EDGAR.

2012 · 17 filings — 11 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms

Counted, not listed; the year is on EDGAR.

2011 · 20 filings — 14 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms

Counted, not listed; the year is on EDGAR.

2010 · 15 filings — 9 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms

Counted, not listed; the year is on EDGAR.

2009 · 16 filings — 9 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms

Counted, not listed; the year is on EDGAR.

2008 · 9 filings — 3 × 10-Q, 3 × 8-K, 1 × 10-K and 2 other forms

Counted, not listed; the year is on EDGAR.

2007 · 7 filings — 3 × 10-Q, 3 × 8-K, 1 × 10-K

Counted, not listed; the year is on EDGAR.

Insider, ownership and other filings#

Insider ownership (Forms 3, 4, 5 and 144), beneficial ownership (Schedules 13D and 13G), registration and prospectus (S-1, S-3, S-8, 424B and related) and the rest, counted by year, with the newest 25 of each of the latest 3 years shown. A Form 4 is one insider’s transaction report; a 13G is a passive holder above five percent.

2026 · 63 filings — 32 × 4, 23 × 144, 5 × SCHEDULE 13G/A and 2 other forms
FiledWhat it is
Sep 28, 2026144Notice of proposed sale (Form 144)
Sep 11, 20264Insider transaction (Form 4)
Sep 11, 2026144Notice of proposed sale (Form 144)
Sep 9, 2026144Notice of proposed sale (Form 144)
Aug 20, 20264Insider transaction (Form 4)
Aug 20, 2026144Notice of proposed sale (Form 144)
Aug 18, 20264Insider transaction (Form 4)
Aug 18, 20263Initial insider holdings (Form 3)
Jul 20, 20264Insider transaction (Form 4)
Jul 20, 2026144Notice of proposed sale (Form 144)
Jun 18, 20264Insider transaction (Form 4)
Jun 18, 20264Insider transaction (Form 4)
Jun 18, 20264Insider transaction (Form 4)
Jun 18, 20264Insider transaction (Form 4)
Jun 18, 20264Insider transaction (Form 4)
Jun 18, 20264Insider transaction (Form 4)
Jun 17, 2026S-8Employee stock plan registration
Jun 1, 20264Insider transaction (Form 4)
Jun 1, 2026144Notice of proposed sale (Form 144)
May 22, 20264Insider transaction (Form 4)
May 22, 2026144Notice of proposed sale (Form 144)
May 18, 20264Insider transaction (Form 4)
May 18, 2026144Notice of proposed sale (Form 144)
May 15, 2026SCHEDULE 13G/AOther filings
May 15, 2026SCHEDULE 13G/AOther filings

The newest 25 of 63 shown; the full year is on EDGAR.

2025 · 106 filings — 52 × 4, 42 × 144, 4 × SCHEDULE 13G/A and 4 other forms
FiledWhat it is
Dec 12, 2025SCHEDULE 13D/AOther filings
Dec 12, 2025SCHEDULE 13D/AOther filings
Dec 12, 20254Insider transaction (Form 4)
Dec 12, 20254Insider transaction (Form 4)
Dec 10, 2025144Notice of proposed sale (Form 144)
Dec 10, 2025144Notice of proposed sale (Form 144)
Dec 4, 20254Insider transaction (Form 4)
Dec 4, 2025144Notice of proposed sale (Form 144)
Dec 3, 20254Insider transaction (Form 4)
Dec 2, 2025144Notice of proposed sale (Form 144)
Nov 21, 20254Insider transaction (Form 4)
Nov 21, 2025144Notice of proposed sale (Form 144)
Nov 14, 20254Insider transaction (Form 4)
Nov 14, 2025SCHEDULE 13G/AOther filings
Nov 13, 2025144Notice of proposed sale (Form 144)
Nov 7, 20254Insider transaction (Form 4)
Nov 5, 2025144Notice of proposed sale (Form 144)
Sep 11, 2025S-8Employee stock plan registration
Sep 9, 2025144Notice of proposed sale (Form 144)
Sep 9, 20254Insider transaction (Form 4)
Aug 29, 2025144Notice of proposed sale (Form 144)
Aug 21, 20254Insider transaction (Form 4)
Aug 21, 2025144Notice of proposed sale (Form 144)
Aug 20, 20254Insider transaction (Form 4)
Aug 20, 20254Insider transaction (Form 4)

The newest 25 of 106 shown; the full year is on EDGAR.

2024 · 77 filings — 38 × 4, 17 × 144, 9 × SC 13G/A and 9 other forms
FiledWhat it is
Dec 5, 20244Insider transaction (Form 4)
Nov 27, 20244Insider transaction (Form 4)
Nov 25, 2024144Notice of proposed sale (Form 144)
Nov 22, 20244Insider transaction (Form 4)
Nov 21, 2024144Notice of proposed sale (Form 144)
Nov 14, 2024SC 13G/APassive holder above 5% (Schedule 13G), amended
Nov 14, 2024SC 13G/APassive holder above 5% (Schedule 13G), amended
Nov 14, 2024SC 13GPassive holder above 5% (Schedule 13G)
Nov 8, 20244Insider transaction (Form 4)
Nov 7, 2024144Notice of proposed sale (Form 144)
Nov 5, 20244Insider transaction (Form 4)
Nov 1, 2024144Notice of proposed sale (Form 144)
Oct 31, 2024S-8Employee stock plan registration
Sep 17, 20244Insider transaction (Form 4)
Sep 11, 20244Insider transaction (Form 4)
Sep 10, 2024144Notice of proposed sale (Form 144)
Aug 19, 20244Insider transaction (Form 4)
Aug 15, 20243Initial insider holdings (Form 3)
Jun 27, 20244Insider transaction (Form 4)
Jun 27, 20244Insider transaction (Form 4)
Jun 27, 20244Insider transaction (Form 4)
Jun 27, 20244Insider transaction (Form 4)
Jun 27, 20244Insider transaction (Form 4)
Jun 27, 20244Insider transaction (Form 4)
Jun 18, 20244Insider transaction (Form 4)

The newest 25 of 77 shown; the full year is on EDGAR.

2023 · 59 filings — 28 × 4, 8 × SC 13G/A, 4 × 3 and 9 other forms

Counted, not listed; the year is on EDGAR.

2022 · 24 filings — 15 × 4, 5 × SC 13G/A, 2 × SC 13G and 2 other forms

Counted, not listed; the year is on EDGAR.

2021 · 31 filings — 16 × 4, 6 × SC 13G/A, 2 × 3 and 6 other forms

Counted, not listed; the year is on EDGAR.

2020 · 29 filings — 20 × 4, 2 × SC 13D/A, 2 × SC 13G and 4 other forms

Counted, not listed; the year is on EDGAR.

2019 · 25 filings — 12 × 4, 4 × SC 13D/A, 2 × 3 and 5 other forms

Counted, not listed; the year is on EDGAR.

2018 · 24 filings — 18 × 4, 2 × 424B5, 2 × SC 13G and 2 other forms

Counted, not listed; the year is on EDGAR.

2017 · 20 filings — 11 × 4, 2 × 424B5, 1 × 424B3 and 6 other forms

Counted, not listed; the year is on EDGAR.

2016 · 34 filings — 13 × 4, 7 × 3, 7 × 4/A and 5 other forms

Counted, not listed; the year is on EDGAR.

2015 · 51 filings — 32 × 4, 8 × SC 13D/A, 3 × 424B5 and 7 other forms

Counted, not listed; the year is on EDGAR.

2014 · 31 filings — 16 × 4, 5 × 3, 3 × 424B5 and 5 other forms

Counted, not listed; the year is on EDGAR.

2013 · 48 filings — 28 × 4, 4 × SC 13D/A, 4 × SC 13G/A and 9 other forms

Counted, not listed; the year is on EDGAR.

2012 · 55 filings — 38 × 4, 5 × 424B5, 4 × SC 13D/A and 5 other forms

Counted, not listed; the year is on EDGAR.

2011 · 38 filings — 27 × 4, 2 × CT ORDER, 2 × SC 13G/A and 7 other forms

Counted, not listed; the year is on EDGAR.

2010 · 42 filings — 26 × 4, 4 × 424B5, 3 × SC 13D/A and 5 other forms

Counted, not listed; the year is on EDGAR.

2009 · 26 filings — 19 × 4, 2 × 5, 2 × SC 13G/A and 3 other forms

Counted, not listed; the year is on EDGAR.

2008 · 34 filings — 18 × 4, 5 × 5, 2 × CT ORDER and 8 other forms

Counted, not listed; the year is on EDGAR.

2007 · 59 filings — 20 × 4, 16 × 3, 4 × 144 and 13 other forms

Counted, not listed; the year is on EDGAR.

2006 · 3 filings — 1 × S-1, 1 × S-1/A, 1 × UPLOAD

Counted, not listed; the year is on EDGAR.

2005 · 6 filings — 4 × S-1/A, 1 × RW, 1 × S-1

Counted, not listed; the year is on EDGAR.

2004 · 4 filings — 2 × REGDEX, 2 × REGDEX/A

Counted, not listed; the year is on EDGAR.

2003 · 2 filings — 1 × REGDEX, 1 × REGDEX/A

Counted, not listed; the year is on EDGAR.

2002 · 2 filings — 2 × REGDEX

Counted, not listed; the year is on EDGAR.

About this data

Madrigal Pharmaceuticals Inc. (MDGL) has 1,217 filings on EDGAR going back to 2002: 24 annual reports, 61 quarterly reports and 190 current reports, plus proxy statements, insider forms and ownership schedules. Its latest annual report, a 10-K, was filed on Feb 19, 2026 for the fiscal year ended Dec 31, 2025. The most recent 8-K, on Aug 12, 2026, covered directors or officers; compensation; regulation fd disclosure. Over the last 13 months insiders sold $40.2M in 20 sales and bought nothing on the open market; 36 other transactions (awards, exercises, tax withholding, gifts and plan purchases). Not investment advice.

Every row is a filing EDGAR lists for the registrants that have been Madrigal Pharmaceuticals Inc., read from the SEC’s submissions index each morning; a filing accepted after that read appears the next day. Where a company changed its filing entity (a holding-company reorganisation, Google into Alphabet) the predecessor’s filings are shown for the years it filed as the company, derived from the filings themselves. Dates are the filing date; the period is the report’s own. The latest 3 years of reports are listed in full, the next years to 10 without their 8-Ks, and older years are counted; the other forms are counted too, with the newest 25 of each of the latest 3 years shown. Insider transactions are the Form 4 and Form 5 documents themselves, filed since January 2026, every number as the insider filed it: a day’s lots are summed, a blank price adds its shares and no dollars, and a purchase through an employee stock plan is a plan purchase, not insider buying. The documents stay on sec.gov, public domain, and every link opens the SEC’s copy. ChartRow does not summarise or interpret filings.

FAQ#

Where can I read MDGL's latest 10-K?
MDGL's latest annual report, a 10-K, was filed on Feb 19, 2026 for the fiscal year ended Dec 31, 2025. It is linked above and opens on EDGAR, the SEC's own site, where every exhibit is also listed.
When did MDGL last file an 8-K?
On Aug 12, 2026: directors or officers; compensation; regulation fd disclosure. An 8-K reports a material event between quarterly reports; the one that furnishes the quarter's results is filed under Item 2.02, last on Jul 30, 2026.
Are MDGL insiders buying or selling?
Over the last 13 months insiders sold $40.2M in 20 sales and bought nothing on the open market; 36 other transactions (awards, exercises, tax withholding, gifts and plan purchases). The most recent sale: Sibold William John (President and CEO · Director) sold 5,221 shares on Sep 11, 2026 for $2.8M, under a 10b5-1 plan. Every figure is as the insider filed it on Form 4; a sale under a 10b5-1 plan was scheduled in advance.
How many SEC filings has MDGL made?
1,217 filings are on EDGAR under the registrant records that have been Madrigal Pharmaceuticals Inc., going back to 2002; 652 of them are insider ownership forms (Forms 3, 4, 5 and 144).